{
     "PMID": "10720637",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20000511",
     "LR": "20141120",
     "IS": "0014-2999 (Print) 0014-2999 (Linking)",
     "VI": "391",
     "IP": "1-2",
     "DP": "2000 Mar 10",
     "TI": "Effects of GYKI 52466 and some 2,3-benzodiazepine derivatives on hippocampal in vitro basal neuronal excitability and 4-aminopyridine epileptic activity.",
     "PG": "75-80",
     "AB": "In order to determine whether the anticonvulsant effect of 2, 3-benzodiazepines is also displayed in a model of in vitro epilepsy, such as the \"epileptiform\" hippocampal slice, we studied the effects of 2,3-benzodiazepine 1-(4-aminophenyl)-4-methyl-7, 8-methylenedioxe-5H 2,3-benzodiazepine hydrochloride (GYKI 52466) and some new 2,3-benzodiazepine derivatives on CA1 basal neuronal excitability and on CA1 epileptiform burst activity produced by 4-aminopyridine in rat hippocampal slices. The results showed that GYKI 52466 affected basal neuronal excitability as evidenced by its influence on the magnitude of the CA1 orthodromic-evoked field potentials. 2,3-Benzodiazepines showed their antiepileptic effect also in an in vitro model of experimental epilepsy. The effects of the new 2,3-benzodiazepine derivatives suggest that the methylenedioxidation in positions 7 and 8 of the 2,3-benzodiazepine ring is the main structural modification for the antiepileptic effect of 2,3-benzodiazepines to take place.",
     "FAU": [
          "Marinelli, S",
          "Gatta, F",
          "Sagratella, S"
     ],
     "AU": [
          "Marinelli S",
          "Gatta F",
          "Sagratella S"
     ],
     "AD": "Laboratorio di Farmacologia, Istituto Superiore di Sanita, Viale Regina Elena 299, Rome, Italy.",
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article"
     ],
     "PL": "Netherlands",
     "TA": "Eur J Pharmacol",
     "JT": "European journal of pharmacology",
     "JID": "1254354",
     "RN": [
          "0 (Anti-Anxiety Agents)",
          "0 (Anticonvulsants)",
          "0 (Calcium Channel Blockers)",
          "0 (Convulsants)",
          "0 (Receptors, Presynaptic)",
          "102771-26-6 (GYKI 52466)",
          "12794-10-4 (Benzodiazepines)",
          "BH3B64OKL9 (4-Aminopyridine)",
          "CJ0O37KU29 (Verapamil)"
     ],
     "SB": "IM",
     "MH": [
          "4-Aminopyridine/*antagonists & inhibitors/pharmacology",
          "Animals",
          "Anti-Anxiety Agents/*pharmacology",
          "Anticonvulsants/*pharmacology",
          "Axons/drug effects",
          "Benzodiazepines/*pharmacology",
          "Calcium Channel Blockers/pharmacology",
          "Convulsants/*antagonists & inhibitors/pharmacology",
          "Electrophysiology",
          "Epilepsy/chemically induced/physiopathology/*prevention & control",
          "Hippocampus/cytology/*drug effects/physiopathology",
          "In Vitro Techniques",
          "Male",
          "Membrane Potentials/drug effects",
          "Neurons/*drug effects",
          "Neurons, Afferent/drug effects",
          "Rats",
          "Rats, Wistar",
          "Receptors, Presynaptic/drug effects",
          "Verapamil/pharmacology"
     ],
     "EDAT": "2000/03/18 09:00",
     "MHDA": "2000/05/16 09:00",
     "CRDT": [
          "2000/03/18 09:00"
     ],
     "PHST": [
          "2000/03/18 09:00 [pubmed]",
          "2000/05/16 09:00 [medline]",
          "2000/03/18 09:00 [entrez]"
     ],
     "AID": [
          "S0014-2999(00)00050-9 [pii]"
     ],
     "PST": "ppublish",
     "SO": "Eur J Pharmacol. 2000 Mar 10;391(1-2):75-80.",
     "term": "hippocampus"
}